{
    "nct_id": "NCT03462719",
    "official_title": "A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).",
    "inclusion_criteria": "* Adult participants who are: (a) greater than or equal to (>=) 65 years old or, (b) 18 to 64 years old and have at least 1 of the following:\n\n  1. Cumulative Illness Rating Scale (CIRS) score > 6\n  2. Creatinine clearance (CrCl) estimated less than (<) 70 milliliter per minute (mL/min) using Cockcroft-Gault equation\n* Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria\n* Measurable nodal disease (by computed tomography [CT]), defined as at least one lymph node > 1.5 centimeter (cm) in longest diameter\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Grade less than or equal to (<=) 2\n* Active CLL/SLL requiring treatment per the iwCLL criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior anti-leukemic therapy for CLL or SLL\n* Presence of deletion of the short arm of chromosome 17 (del17p) or known TP53 mutation detected at a threshold of >10 percent (%) variable allele frequency (VAF)\n* Major surgery within 4 weeks of first dose of study treatment\n* Known bleeding disorders (example, von Willebrand's disease or hemophilia)\n* Central nervous system (CNS) involvement or suspected Richter's syndrome",
    "miscellaneous_criteria": ""
}